Inhibitor-sensitive fgfr1 amplification in human non-small cell lung cancer

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Dutt, Amit ^a,b,e   Ramos, Alex H ^a,b,d   Hammerman, Peter S ^a   Mermel, Craig ^a,b   Cho, Jeonghee ^a   Sharifnia, Tanaz ^a,b   Chande, Ajit ^e   Tanaka, Kumiko Elisa ^a,b   Stransky, Nicolas ^b   Greulich, Heidi ^a,b,c   Gray, Nathanael S ^a,d   Meyerson, Matthew ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; GENE PRODUCT; PROTEIN LETM2; PROTEIN WHSC1L1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; FGFR1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL GROWTH; CHROMOSOME 8P; CONTROLLED STUDY; FIBROBLAST GROWTH FACTOR RECEPTOR TYPE 1 GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LETM2 GENE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WHSC1L1 GENE; 3' UNTRANSLATED REGION; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE LOCUS; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; OPEN READING FRAME; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE AMPLIFICATION; GENE KNOCKDOWN TECHNIQUES; GENETIC LOCI; HUMANS; LUNG NEOPLASMS; OPEN READING FRAMES; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, SMALL INTERFERING;

EID: 79958112619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020351     Document Type: Article

References (62)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Minna JD, Roth JA, Gazdar AF, (2002) Focus on lung cancer. Cancer Cell 1: 49-52.
3. Wistuba II, (2007) Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 7: 3-14.
4. Selvaggi G, Scagliotti GV, (2009) Histologic subtype in NSCLC: does it matter? Oncology (Williston Park) 23: 1133-1140.
5. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
6. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
10. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
11. Neal JW, Sequist LV, (2010) Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 11: 36-44.
12. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
13. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
14. Zheng J, Shu Q, Li ZH, Tsao JI, Weiss LM, et al. (1994) Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age. Am J Pathol 145: 1444-1449.
15. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, et al. (2007) PIK3CA mutation and amplification in human lung cancer. Pathol Int 57: 664-671.
16. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
17. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103: 7817-7822.
18. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, et al. (2011) Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery; Published OnlineFirst April 3, 2011; doi:10.1158/2159-8274.CD-11-0005.
19. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, et al. (2009) Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 69: 3937-3946.
20. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, et al. (2009) Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 8: 2042-2050.
21. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, et al. (2010) Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma. PLoS Med 7: e1000315.
22. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, et al. (2011) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93.
23. Krause DS, Van Etten RA, (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187.
24. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
25. Bardelli A, Siena S, (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261.
26. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
27. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, et al. (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368.
28. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
29. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
30. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, et al. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21: 255-262.
31. Turner N, Grose R, (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
32. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, et al. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16: 260-264.
33. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, et al. (1997) A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90: 4062-4070.
34. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, et al. (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61: 1265-1268.
35. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 105: 8713-8717.
36. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, et al. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 7158-7162.
37. Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, et al. (2007) Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 43: 60-66.
38. Ishizuka T, Tanabe C, Sakamoto H, Aoyagi K, Maekawa M, et al. (2002) Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun 296: 152-155.
39. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, et al. (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13: 4731-4739.
40. Simon R, Richter J, Wagner U, Fijan A, Bruderer J, et al. (2001) High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61: 4514-4519.
41. Edwards J, Krishna NS, Witton CJ, Bartlett JM, (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9: 5271-5281.
42. Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, et al. (2009) Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 48: 455-467.
43. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, et al. (2007) Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A 104: 16663-16668.
44. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102: 9625-9630.
45. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
46. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570.
47. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, et al. (2009) Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75: 196-207.
48. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
49. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24: 32-91.
50. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119: 1727-1740.
51. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24: 32-91.
52. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
53. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
54. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283-1298.
55. Zhou W, Hur W, McDermott U, Dutt A, Xian W, et al. (2010) A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol 17: 285-295.
56. Kim SM, Kee HJ, Eom GH, Choe NW, Kim JY, et al. (2006) Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity. Biochem Biophys Res Commun 345: 318-323.
57. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
58. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
59. Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, et al. (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24: 8259-8267.
60. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, et al. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14: 2075-2081.
61. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782.
62. Machida S, Saga Y, Takei Y, Mizuno I, Takayama T, et al. (2005) Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer 114: 224-229.